Biotech | March 01, 2022
Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period
High level of vaccine efficacy maintained over a 6-month period of surveillance
High level of vaccine efficacy maintained over a 6-month period of surveillance
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
Study to evaluate effectiveness of hypoglossal nerve stimulation
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains
100% efficacy against severe Covid-19 disease and hospitalizations
Subscribe To Our Newsletter & Stay Updated
